Auro Laboratories
- Market cap
- ₹ 134 Cr.
- P/E
- 77.7x
- P/B
- 2.88x
- 52-week range
- 159 – 317
- ROE
- 8%
- ROCE
- 9.5%
- Dividend yield
- 0%
- Debt / equity
- 1.37
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- BSE
About
Auro Laboratories Limited is an India-based company, which is engaged in the manufacturing activities of active pharmaceutical ingredients (APIs). The Company is specializing in producing anti-diabetics like Metformin HCL, which is used in the treatment of type 2 diabetes. It also undertakes toll/custom manufacturing for API's and intermediates on a contract basis. The Company's API products include antihistamine, muscle relaxant, diuretic, iron deficiency, anti-diabetics, anti-fungal, anti-ulcer, iodine supplement, anti-malaria, analgesics, antacids, anti-inflammatory, specialty chemicals and others. Its intermediate products include glibenclamde sulphonamide, cis-bramo benzoate, cls-tosylate, 2-ethoxy benzoic acid, 2-ethoxy benzoic acid, among others. It offers its manufacturing and technical services, such as process scale up, process optimization, custom synthesis and custom manufacturing. It exports to Southeast Asia, Middle East and several European countries.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Auro Laboratories against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)77.7 against a typical 34.6: pricier than most peers (1st = cheapest).181st of 220
- Sales growth+216.6% against a typical +15.6% from a year earlier.10th of 197
- Share price, 3 months−0.6% against a typical −0.5%.102nd of 200
- Size₹ 134.1 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).135th of 199
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13 | 18 | 12 | 6 | 3 | 3 | 7 | 3 | 9 | 9 | 10 | 9 |
| Expenses | 10 | 14 | 10 | 4 | 2 | 3 | 7 | 3 | 6 | 5 | 7 | 5 |
| Operating Profit | 3 | 4 | 2 | 1 | 1 | 0 | 1 | 0 | 2 | 4 | 3 | 3 |
| OPM % | 22.6% | 22.7% | 20% | 23.3% | 23.2% | 14.8% | 11% | 1.1% | 26.6% | 43.2% | 33.9% | 37.6% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Interest | 0 | 0 | −0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Profit before tax | 3 | 4 | 3 | 1 | 0 | 0 | 0 | −0 | 2 | 2 | 1 | 1 |
| Tax % | 27.8% | 27.7% | 18.6% | 24.8% | 25% | 28.6% | −11.4% | 0% | 58.1% | −12.1% | 32.9% | 7.1% |
| Net Profit | 2 | 3 | 2 | 1 | 0 | 0 | 0 | −0 | 1 | 2 | 1 | 1 |
| EPS in Rs | 3.16 | 4.38 | 3.72 | 1.2 | 0.58 | 0.08 | 0.63 | −0.18 | 1.16 | 3.13 | 1.56 | 1.68 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 1%
- 5 Years
- −11%
- 3 Years
- −17%
- TTM
- 126%
- 10 Years
- 16%
- 5 Years
- −12%
- 3 Years
- 16%
- TTM
- 594%
- 10 Years
- 22%
- 5 Years
- 14%
- 3 Years
- 43%
- TTM
- —
- 10 Years
- 14%
- 5 Years
- 10%
- 3 Years
- 11%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Auro Laboratories | ₹ 233.70 | ₹ 134 Cr. | 77.7x | 2.9x | 8% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Sharat Deorah
- Executive Chairman of the Board, Managing Director
- Nitesh Bohra
- Chief Financial Officer
- Padma Tapariya
- Compliance Officer, Company Secretary
- Siddhartha Deorah
- Whole-Time Director
- Kiran Suresh Kulkarni
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.